-
New publication, Key Developments in Novel Therapies for Bleeding Disorders
The CHS, in collaboration with the Irish Haemophilia Society, is producing a new print publication, Key Developments in Novel Therapies for Bleeding Disorders. It is...
-
British Columbia, Ontario approve access to gene therapy for hemophilia B
Montreal – April 3, 2026 – In the last few weeks, British Columbia and Ontario have approved access to HEMGENIX, gene therapy for hemophilia B....
-
PROBE Survey Reminder, News for People with VWD
Montreal, February 27, 2026 – A group of MyCBDR users will have received an email in recent days inviting them to complete the PROBE survey....
-
BEYOND-9 hemophilia B gene therapy clinical trial launched in four Canadian study sites
Montreal, February 5, 2026 – Four Canadian bleeding disorder treatment centres are participating in the Phase 1 clinical trial of Regeneron’s CRISPR/Cas9-based targeted gene insertion...
-
The CHS pressures provinces to reimburse hemophilia B gene therapy
Montréal, December 17, 2025 – The Canadian Hemophilia Society (CHS) has written to the Provincial/Territorial Ministers of Health (excluding Quebec) to urge them to add...